Inovio Pharmaceuticals (NASDAQ:INO) has tumbled 1.41% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 0.19% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.23%. Inovio Pharmaceuticals (NASDAQ:INO) has underperformed the index by 0.72% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Inovio Pharmaceuticals (NASDAQ:INO): The stock opened at $10.80 on Friday but the bulls could not build on the opening and the stock topped out at $10.87 for the day. The stock traded down to $10.45 during the day, due to lack of any buying support eventually closed down at $10.47 with a loss of -2.51% for the day. The stock had closed at $10.74 on the previous day. The total traded volume was 1,898,919 shares.
The company shares have rallied 17.38% from its 1 Year high price. On Apr 28, 2016, the shares registered one year high at $11.69 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $10.43 and the 200 Day Moving Average price is recorded at $7.99.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Benito Simon X, director of Inovio Pharmaceuticals, Inc., had unloaded 6,250 shares at an average price of $10.37 in a transaction dated on May 18, 2016. The total value of the transaction was worth $64,813.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Brean Capital, maintains their rating on the shares of Inovio Pharmaceuticals (NASDAQ:INO). Brean Capital has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $18 per share from a prior target of $20. The rating by the firm was issued on March 14, 2016. Currently the company Insiders own 9.9% of Inovio Pharmaceuticals shares according to the proxy statements. Institutional Investors own 27.31% of Inovio Pharmaceuticals shares.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.